Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab
Comprehensive insights on the clinical management of adverse events from talquetamab seen in patients with multiple myeloma, including cytokine release syndrome and infections.
EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?
EP: 2.Overview of Relapsed/Refractory Multiple Myeloma
EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM
EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM
EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab
EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma
EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities
EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management
EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma
EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma
This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
For cytokine release syndrome (CRS) management with tocilizumab, Mount Sinai Health System in New York, New York, employs early intervention with tocilizumab at initial fever onset, avoiding corticosteroids initially. Memorial Sloan Kettering Cancer Center in New York, New York, also uses early tocilizumab trigger at first fever, having overcome hesitancy from chimeric antigen receptor T-cell therapy experience given lack of efficacy impact.
Regarding infection prophylaxis with talquetamab, varicella-zoster virus and Pneumocystis jirovecii pneumonia prophylaxis are used, with little other antimicrobial prophylaxis unless prior infection directs tailored approaches. Some differences persist in GPRC5D infectious risk precaution vs BCMA regimens.
Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
